UNSPSC 51413801: Podilfen

This classification denotes a vasodilating agent with the molecular formula C18H23N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LI81FMI713, chemically known as 1-(alpha-methyl-3,4-(methylenedioxy)phenethyl)-4-(4-methyl-2-thiazolyl)piperazine. but generally known as podilfen, which bears US NIH Compound Identifier 3050403. European Medicines Agency schedules Podilfen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09962MIG.

UNSPSC 51413801 Podilfen, a Commodity code, covers emergency and clinical pharmaceutical supplies—specifically advanced life support medications and generic multi-source pharmaceuticals—that state and local health agencies and first-responder departments procure for treatment delivery and inventory replenishment. State and local governments buy under this code primarily through fire rescue services, health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Recent activity shows city fire departments and state health agencies soliciting sealed bids and RFPs for specific medication line items (epinephrine, labetalol, adenosine, diltiazem vials and injections), generic pharmaceuticals through authorized wholesaler distribution channels, and exploratory procurement to evaluate direct-to-manufacturer supply models outside traditional pharmacy benefit manager arrangements.

The City of Tampa's Purchasing Department and the Texas Health and Human Services Commission dominate recent activity, joined by the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which coordinates purchasing across Minnesota, Oregon, and participating state and local facilities. Geographic activity spans Florida, Texas, and Minnesota with multi-state reach through cooperative arrangements. The City of Tampa issued IFB 26P00188 for Advanced Life Support Medications due April 8, 2026, with an estimated contract value of $40,000 and a five percent small local business enterprise bid discount available; Texas HHS posted an exploratory RFI (HHS0017013) on direct-to-manufacturer prescription programs to inform future formal procurement strategy; and MMCAP released a multi-award RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products due March 26, 2026, requiring manufacturers to supply through three authorized wholesalers with pricing weighted at 75 percent of evaluation, effective July 1, 2026. All recent opportunities require compliance with FDA standards, expiration-date minimums, and OSHA hazard communication standards for safety data sheets.